REG - Anpario PLC - UK patent granted for Orego-stim

AnparioAnnouncement

03/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211203:nRSC4522Ua&default-theme=true

RNS Number : 4522U  Anpario PLC  03 December 2021

Anpario plc
("Anpario" or the "Company")

 

Orego-stim patent granted for reducing antimicrobial resistance

 

Anpario, the independent manufacturer of natural sustainable animal feed
additives for health, nutrition, and biosecurity, is pleased to confirm it has
successfully been granted a UK patent for market leading phytogenic product
Orego-Stim.

 

The patent grant follows a combined and successful research programme with the
University of Reading. This research shows that the natural oregano oil
composition reduces the proportion of bacteria in the gut that show
antimicrobial resistance, when added to the diets of young cattle. This
resistance can occur when calves are fed 'waste milk' or colostrum containing
antibiotic residues. This 'waste milk', which also contains beneficial
microbes for metabolism and immunity, is a major by-product of the dairy
industry which cannot be sold for human consumption and so instead, is
commonly fed to calves.

 

The inhibition effects of the Orego-Stim on antimicrobial resistance means
that those 'highest priority and critically important' antibiotics commonly
used in human and animal medicine, such as cephalosporins can be safeguarded
for future use. There are other positive aspects to this research which
support Anpario's strategy of extending our product technology to maintain
animal health through scientific applications.

 

It is hoped that the UK patent will provide a tax benefit to the Group via the
UK Patent Box scheme which allows companies to apply a lower rate of
corporation tax to profits attributable to qualifying patents. We are
currently working with our tax and patent advisors to clarify the scope of
qualifying profits and the tax benefit.

 

Further details regarding the research trial can be found on the following
link:
https://www.anpario.com/media/news/university-trial-shows-anparios-orego-stim-can-help-reduce-antimicrobial-resistance-in-calves/
(https://www.anpario.com/media/news/university-trial-shows-anparios-orego-stim-can-help-reduce-antimicrobial-resistance-in-calves/)

 

 

 

Enquiries:

 Anpario plc
 Richard Edwards, CEO                 +44(0) 777 6417 129
 Marc Wilson, Group Finance Director  +44(0) 1909 537380

 Peel Hunt LLP (NOMAD)                +44 (0)20 7418 8900
 Adrian Trimmings
 Andrew Clark
 Will Bell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSUEEEEFSEDE